Last reviewed · How we verify
Enalapril plus Losartan
At a glance
| Generic name | Enalapril plus Losartan |
|---|---|
| Also known as | Anapril plus Loranta, Enalapril plus Losartan group |
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies (PHASE4)
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enalapril plus Losartan CI brief — competitive landscape report
- Enalapril plus Losartan updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI